市場調查報告書

頑固型心絞痛:市場分析、流行病學、市場預測 (2030年)

Refractory Angina - Market Insights, Epidemiology and Market Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 938683
出版日期 內容資訊 英文 131 Pages
商品交期: 最快1-2個工作天內
價格
頑固型心絞痛:市場分析、流行病學、市場預測 (2030年) Refractory Angina - Market Insights, Epidemiology and Market Forecast-2030
出版日期: 2020年05月01日內容資訊: 英文 131 Pages
簡介

頑固型心絞痛(RA),特徵是由於斑塊的積蓄造成部分或完全阻斷心肌(心臟的肌肉)的血流的可逆性心肌缺血導致持續性心絞痛,衰弱性慢性狀態。根據DelveInsight,全球主要7個國家(美國,德國,西班牙,義大利,法國,英國,日本) 的頑固型心絞痛(RA)的患病案例的總數2017年是29,17,196。主要7個國家的頑固型心絞痛市場規模,從2017年到2030年之間年複合成長率預計增加7.00%。

本報告提供全球主要7個國家 (美國、德國、西班牙、義大利、法國、英國、日本) 的頑固型心絞痛 (RA) 市場相關調查,市場及疾病概要,性別、各子類型、各國流行病學的預測,未滿足需求,已上市治療藥及新藥概要,整體及各國的市場規模的變化與預測,市場成長要素及障礙分析等。

第1章 主要考察

第2章 頑固型心絞痛:摘要整理

第3章 頑固型心絞痛:SWOT分析

第4章 頑固型心絞痛(RA):市場概要

第5章 疾病的背景和概要

  • 簡介
  • 類型
  • 症狀
  • 病因
  • 危險因素
  • 病理學
  • 診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的頑固型心絞痛 (RA)的總患者數

第7章 流行病學的假設和根據:主要7個國家

第8章 頑固型心絞痛(RA)的流行病學:各國

  • 美國
    • CAD及RA的罹患者總數
    • RA盛行率:各子類型
    • RA盛行率:性別
    • NORDA罹患者數
  • 德國
    • CAD及RA的罹患者總數
    • RA盛行率:各子類型
    • RA盛行率:性別
    • NORDA罹患者數
  • 法國
  • 義大利
  • 西班牙
  • 英國
    • CAD及RA的罹患者總數
    • RA盛行率:各子類型
    • RA盛行率:性別
    • NORDA罹患者數
  • 日本

第9章 治療方法

  • 藥物治療
  • 非侵入性的心絞痛治療
  • 侵入性抗心絞痛療法
  • 治療指南

第10章 未滿足需求

第11章 案例研究

  • 頑固型心絞痛範例
  • 頑固型心絞痛的病例報告

第12章 頑固型心絞痛相關的組織

第13章 新治療藥

  • IMB-101:Umbria Pharmaceuticals
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
  • Auto CD34 + Cells:Calandrias Biosciences,Inc.
  • Generx:Antiemetics Inc.
  • XC001:XyloCor Therapeutics,Inc.

第14章 市場分析頑固型心絞痛(RA):主要7個國家

  • 主要調查結果
  • 的RA的總合市場規模主要7個國家
  • 市場預測:主要7個國家

第15章 美國

  • RA的總合市場規模
  • RA市場規模:各治療藥物

第16章 歐洲5個國家

  • 德國
    • RA的總合市場規模
    • RA市場規模:各治療藥物
  • 法國
  • 義大利
  • 西班牙
  • 英國

第17章 日本

  • RA的總合市場規模
  • RA市場規模:各治療藥物

第18章 市場成長要素

第19章 市場障礙

第20章 附錄

第21章 DelveInsight的服務內容

第22章 免責聲明

第23章 關於DelveInsight

目錄
Product Code: DIMI0606

DelveInsight's 'Refractory Angina (RA)-Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the Refractory Angina, historical and forecasted epidemiology as well as the Refractory Angina market trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Refractory Angina market report provides current treatment practices, emerging drugs, Refractory Angina market share of the individual therapies, current and forecasted Refractory Angina market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Refractory Angina treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Refractory Angina (RA) Disease Understanding and Treatment Algorithm

Refractory Angina Overview

Refractory Angina (RA) is a debilitating chronic condition marked by persistent angina due to reversible myocardial ischemia owing to partial or complete blockage of the blood flow through myocardium (heart muscle) by a buildup of plaques. It is a common reoccurring form of angina resulting from an imbalance between oxygen supply and demand, which encompasses neurological, psychogenic and mitochondrial dysfunctions that, in addition to tissue ischemia, are responsible for persistent cardiac pain syndrome. It is usually reflected in patients with coronary artery disease (CAD) which cannot be adequately controlled by a combination of medical therapy, angioplasty, or coronary artery bypass grafting.

Refractory Angina Diagnosis

Diagnosis of anginal pain is challenging. The clinical signs of angina pectoris are atypical as they are provoked by exertion and disappear at rest. However, the accurate diagnosis of stable angina and recognition of proper pathological mechanisms relies mostly on the detailed clinical history of an individual. The severity of the disease also depends upon the extent of underlying CAD. Besides, the diagnosis of chronic chest pain aims at making the investigation quicker and efficient.

Angina pectoris is said to be refractory if constant reversible myocardial ischemia and pain occur despite optimal anti-anginal therapy in cases with substantial stenosis of a significant coronary artery (more than 75% stenosis in one or more of the main coronary arteries). The NICE recommends two types of testing:

  • (i) Anatomical testing: which diagnoses coronary artery luminal narrowing
  • (ii) Non-invasive functional testing: which diagnoses myocardial ischemia based on the estimated pretest likelihood of CAD. However, there are some other tests too. 

Refractory Angina Treatment

It covers the details of conventional and current medical therapies available in the Refractory Angina market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.

The DelveInsight Refractory Angina market report gives a thorough understanding of Refractory Angina by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Refractory Angina treatment algorithms and treatment guidelines for Refractory Angina in the US, Europe, and Japan.

Refractory Angina Epidemiology

The Refractory Angina epidemiology division provide the insights about historical and current Refractory Angina patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Refractory Angina epidemiology [segmented as Refractory Angina Total Diagnosed Cases of CAD and RA, Refractory Angina Sub-Type Specific Cases, Refractory Angina Gender-Specific Cases and Diagnosed Population of NORDA] scenario of Refractory Angina in 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017 to 2030. According to DelveInsight, the total number of prevalent cases of Refractory Angina (RA) in 7MM was found to be 29,17,196 in the year 2017.

Country Wise- Refractory Angina Epidemiology

The epidemiology segment also provides the Refractory Angina epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom) and Japan.

Refractory Angina Drug Chapters

Drug chapter segment of the Refractory Angina report encloses the detailed analysis of Refractory Angina marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Refractory Angina clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Refractory Angina Marketed Drugs

The first-line anti-anginal drugs include the use of beta-adrenergic receptors and calcium channel blockers. They have proven their efficacy in treating angina and myocardial ischemia. Generally, the choice between these two drug classes is guided by contraindications, the presence of comorbidities and patient preference. If one of these agents is not well tolerated, the other can be tried instead.

Refractory Angina Emerging Drugs

IMB-101: Imbria Pharmaceuticals

IMB-101 is a small molecule currently in development for the treatment of refractory angina by Imbria Pharmaceuticals. IMB-101 is a novel pFOX (partial fatty acid oxidation) inhibitor which is designed to optimize the use of fuels in the heart by partially shifting from using fat to using glucose, thereby resulting in more efficient production of energy per molecule of oxygen consumed. This approach has been validated by trimetazidine (TMZ), a pFOX inhibitor used to treat angina in Europe since the 1970s.

Refractory Angina Market Outlook

The Refractory Angina market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Refractory Angina market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of Refractory Angina market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Refractory Angina market in 7MM is expected to increase with a CAGR of 7.00% during the period 2017-2030.

Key Findings

This section includes a glimpse of the Refractory Angina market in 7MM.

The United States Market Outlook

This section provides the total Refractory Angina market Size and market Size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Refractory Angina market Size and market Size by therapies in Germany, France, Italy, Spain and the United Kingdom is provided in this section.

Japan Market Outlook

The total Refractory Angina market Size and market Size by therapies in Japan is also mentioned.

Refractory Angina Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Refractory Angina market or expected to get launched in the market during the study period 2017-2030. The analysis covers Refractory Angina market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and Size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Refractory Angina Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Refractory Angina key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Refractory Angina emerging therapies.

Reimbursement Scenario in Refractory Angina

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In report we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Refractory Angina domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Refractory Angina market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Refractory Angina Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Refractory Angina, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Refractory Angina epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Refractory Angina are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Refractory Angina market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Refractory Angina market

Report Highlights:

  • In the coming years, Refractory Angina market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Angina R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Refractory Angina. Launch of emerging therapies, will significantly impact the Refractory Angina market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Refractory Angina
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Refractory Angina Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Refractory Angina Pipeline Analysis
  • Refractory Angina Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Refractory Angina Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Refractory Angina Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Refractory Angina Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Refractory Angina Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Refractory Angina total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Refractory Angina market Size during the forecast period (2017-2030)?
  • At what CAGR, the Refractory Angina market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Refractory Angina market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Refractory Angina market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Refractory Angina?
  • What is the historical Refractory Angina patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Refractory Angina in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Refractory Angina?
  • Out of all 7MM countries, which country would have the highest prevalent population of Refractory Angina during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Refractory Angina along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Refractory Angina (RA) in USA, Europe and Japan?
  • What is the Refractory Angina marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy etc.?
  • How many companies are developing therapies for the treatment of Refractory Angina?
  • How many therapies are developed by each company for the treatment of Refractory Angina?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Refractory Angina?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Refractory Angina therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Refractory Angina and their status?
  • What are the key designations that have been granted for the emerging therapies for Refractory Angina?
  • What are the global historical and forecasted market of Refractory Angina?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Refractory Angina market
  • To understand the future market competition in the Refractory Angina market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Refractory Angina in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Refractory Angina market
  • To understand the future market competition in the Refractory Angina market

Table of Contents

1: Key Insights

2: Executive Summary of Refractory Angina

3: SWOT Analysis for Refractory Angina

4: Refractory Angina (RA) Market Overview at a Glance

  • 4.1: Market Share (%) Distribution of Refractory Angina (RA) in 2017
  • 4.2: Market Share (%) Distribution of Refractory Angina (RA) in 2030

5: Disease Background and Overview

  • 5.1: Introduction
  • 5.2: Types
  • 5.3: Symptoms
  • 5.4: Etiology
  • 5.5: Risk Factors
  • 5.6: Pathophysiology
  • 5.7: Diagnosis

6: Epidemiology and Patient Population

  • 6.1: Key Findings
  • 6.2:7MM Total Prevalent Patient Population of Refractory Angina [RA]

7: Epidemiology Assumptions and Rationale - 7MM

8: Country Wise-Epidemiology of Refractory Angina (RA)

  • 8.1: The United States
    • 8.1.1: Total Diagnosed Population of CAD and RA in the United States
    • 8.1.2: Sub-type Specific Prevalence of RA in the United States
    • 8.1.3: Gender specific Prevalence of RA in the United States
    • 8.1.4: Diagnosed Population of NORDA in the US
  • 8.2: Germany
    • 8.2.1: Total Diagnosed Population of CAD and RA in Germany
    • 8.2.2: Sub-type Specific Prevalence of RA in Germany
    • 8.2.3: Gender specific Prevalence of RA in Germany
    • 8.2.4: Diagnosed Population of NORDA in Germany
  • 8.3: France
    • 8.3.1: Total Diagnosed Population of CAD and RA in France
    • 8.3.2: Sub-type Specific Prevalence of RA in France
    • 8.3.3: Gender specific Prevalence of RA in France
    • 8.3.4: Diagnosed Population of NORDA in France
  • 8.4: Italy
    • 8.4.1: Total Diagnosed Population of CAD and RA in Italy
    • 8.4.2: Sub-type Specific Prevalence of RA in Italy
    • 8.4.3: Gender specific Prevalence of RA in Italy
    • 8.4.4: Diagnosed Population of NORDA in Italy
  • 8.5: Spain
    • 8.5.1: Total Diagnosed Population of CAD and RA in Spain
    • 8.5.2: Sub-type Specific Prevalence of RA in Spain
    • 8.5.3: Gender specific Prevalence of RA in Spain
    • 8.5.4: Diagnosed Population of NORDA in Spain
  • 8.6: The United Kingdom
    • 8.6.1: Total Diagnosed Population of CAD and RA in the UK
    • 8.6.2: Sub-type Specific Prevalence of RA in the UK
    • 8.6.3: Gender specific Prevalence of RA in the United Kingdom
    • 8.6.4: Diagnosed Population of NORDA in the United Kingdom
  • 8.7: Japan
    • 8.7.1: Total Diagnosed Population of CAD and RA in Japan
    • 8.7.2: Sub-type Specific Prevalence of RA in Japan
    • 8.7.3: Gender specific Prevalence of RA in Japan
    • 8.7.4: Diagnosed Population of NORDA in Japan

9: Treatment

  • 9.1: Pharmacological Therapies
  • 9.2: Noninvasive Antianginal therapies
  • 9.3: Invasive Antianginal therapies
  • 9.4: Treatment Guidelines
    • 9.4.1: European Society of Cardiology (ESC) Guidelines for Refractory Angina Patients
    • 9.4.2: National Institute for Health and Clinical Excellence (NICE) guidelines: Chest pain of recent onset
    • 9.4.3: Canadian Cardiovascular Society (CCS) Guidelines

10: Unmet Needs

11: Case Studies

  • 11.1: A Case of Refractory Angina
  • 11.2: A Case Report of Refractory Angina

12: Organizations related with Refractory Angina

13: Emerging Therapies

  • 13.1: IMB-101: Umbria Pharmaceuticals
    • 13.1.1: Other Developmental Activities
    • 13.1.2: Clinical Development
    • 13.1.3: Safety and Efficacy
  • 13.2: Auto CD34+ Cells: Calandrias Biosciences, Inc.
    • 13.2.1: Other Developmental Activities
    • 13.2.2: Clinical Development
    • 13.2.3: Safety and Efficacy
  • 13.3: Generx: Antiemetics Inc.
    • 13.3.1: Other Developmental Activities
    • 13.3.2: Clinical Development
    • 13.3.3: Safety and Efficacy
  • 13.4: XC001: XyloCor Therapeutics, Inc.
    • 13.4.1: Other Developmental Activities
    • 13.4.2: Clinical Development

14: Refractory Angina (RA): 7 Major Market Analysis

  • 14.1: Key Findings
  • 14.2: Total Market Size of RA in 7MM
  • 14.3: Market Outlook: 7MM

15: United States

  • 15.1: Total Market size of RA
  • 15.2:RA Market Size by Therapies

16:EU5 Countries

  • 16.1: Germany
    • 16.1.1: Total Market size of RA
    • 16.1.2:RA Market Size by Therapies
  • 16.2: France
    • 16.2.1: Total Market size of RA
    • 16.2.2:RA Market Size by Therapies
  • 16.3: Italy
    • 16.3.1: Total Market size of RA
    • 16.3.2:RA Market Size by Therapies
  • 16.4: Spain
    • 16.4.1: Total Market size of RA
    • 16.4.2:RA Market Size by Therapies
  • 16.5: United Kingdom
    • 16.5.1: Total Market size of RA
    • 16.5.2:RA Market Size by Therapies

17: Japan

  • 17.1: Total Market size of RA
  • 17.2:RA Market Size by Therapies

18: Market Drivers

19: Market Barriers

20: Appendix

  • 20.1: Bibliography
  • 20.2: Report Methodology

21: DelveInsight Capabilities

22: Disclaimer

23: About DelveInsight

List of Tables

  • Table 1: Summary of Refractory Angina (RA) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Difference between Stable and Unstable Angina
  • Table 3: Probability of Coronary Artery Diseases and Associated Diagnostic Strategies
  • Table 4: Total Prevalent Patient Population of RA in 7MM (2017-2030)
  • Table 5: Diagnosed Population of CAD and RA in the United States (2017-2030)
  • Table 6: Sub-type Specific Prevalence of RA in the United States (2017-2030)
  • Table 7: Gender specific Prevalence of RA in the United States (2017-2030)
  • Table 8: Diagnosed Population of NORDA in the US (2017-2030)
  • Table 9: Total Prevalent Population of RA in Germany (2017-2030)
  • Table 10: Sub-type Specific Prevalence of RA in Germany (2017-2030)
  • Table 11: Gender specific Prevalence of RA in Germany (2017-2030)
  • Table 12: Diagnosed Population of NORDA in Germany (2017-2030)
  • Table 13: Diagnosed Population of CAD and RA in France (2017-2030)
  • Table 14: Sub-type Specific Prevalence of RA in France (2017-2030)
  • Table 15: Gender specific Prevalence of RA in France (2017-2030)
  • Table 16: Diagnosed Population of NORDA in France (2017-2030)
  • Table 17: Diagnosed Population of CAD and RA in Italy (2017-2030)
  • Table 18: Sub-type Specific Prevalence of RA in Italy (2017-2030)
  • Table 19: Gender specific Prevalence of RA in Italy (2017-2030)
  • Table 20: Diagnosed Population of NORDA in Italy (2017-2030)
  • Table 21: Diagnosed Population of CAD and RA in Spain (2017-2030)
  • Table 22: Sub-type Specific Prevalence of RA in Italy (2017-2030)
  • Table 23: Gender specific Prevalence of RA in Spain (2017-2030)
  • Table 24: Diagnosed Population of NORDA in Spain (2017-2030)
  • Table 25: Diagnosed Population of CAD and RA in the UK (2017-2030)
  • Table 26: Sub-type Specific Prevalence of RA in the UK (2017-2030)
  • Table 27: Gender specific Prevalence of RA in the United Kingdom (2017-2030)
  • Table 28: Diagnosed Population of NORDA in the UK (2017-2030)
  • Table 29: Diagnosed Population of CAD and RA in Japan (2017-2030)
  • Table 30: Sub-type Specific Prevalence of RA in Japan (2017-2030)
  • Table 31: Gender specific Prevalence of RA in Japan (2017-2030)
  • Table 32: Diagnosed Population of NORDA in Japan (2017-2030)
  • Table 33: Grading of Angina Pectoris
  • Table 34: Organizations contributing toward Refractory Angina
  • Table 35: IMB-101, Clinical Trial Description, 2020
  • Table 36: Auto CD34+ cells, Clinical Trial Description, 2020
  • Table 37: Generx, Clinical Trial Description, 2020
  • Table 38: XC001, Clinical Trial Description, 2020
  • Table 39: 7 Major Market Size of RA in USD Million (2017-2030)
  • Table 40: The US Market size of RA in USD Million (2017-2030)
  • Table 41: The US market size of RA by Therapies in USD Million (2017-2030)
  • Table 42: Germany Market size of RA in USD Million (2017-2030)
  • Table 43: Germany market size of RA by Therapies in USD Million (2017-2030)
  • Table 44: France Market size of RA in USD Million (2017-2030)
  • Table 45: France market size of RA by Therapies in USD Million (2017-2030)
  • Table 46: Italy Market size of RA in USD Million (2017-2030)
  • Table 47: Italy market size of RA by Therapies in USD Million (2017-2030)
  • Table 48: Spain Market size of RA in USD Million (2017-2030)
  • Table 49: Spain market size of RA by Therapies in USD Million (2017-2030)
  • Table 50: The UK Market size of RA in USD Million (2017-2030)
  • Table 51: The UK market size of RA by Therapies in USD Million (2017-2030)
  • Table 52: Japan Market size of RA in USD Million (2017-2030)
  • Table 53: Japan market size of RA by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Normal and Plaque Buildup Artery
  • Figure 3: Pictorial Representation of Different Types of Angina
  • Figure 4: Few of the causes of Chest Pain
  • Figure 5: Mechanisms and Pathways involved in Cardiac Chest Pain
  • Figure 6: The Heart-Brain Axis Model of Angina Physiopathology and Related Therapeutic Targets
  • Figure 7: Diagnosis of Chest Pain Symptoms according to Anginal Symptoms
  • Figure 8: Diagnostic Interventions
  • Figure 9: Definite Diagnosis
  • Figure 10: Total Prevalent Patient Population of RA in 7MM (2017-2030)
  • Figure 11: Diagnosed Population of CAD and RA in the United States (2017-2030)
  • Figure 12: Sub-type Specific Prevalence of RA in the United States (2017-2030)
  • Figure 13: Gender specific Prevalence of RA in the United States (2017-2030)
  • Figure 14: Diagnosed Population of NORDA in the US (2017-2030)
  • Figure 15: Diagnosed Population of CAD and RA in Germany (2017-2030)
  • Figure 16: Sub-type Specific Prevalence of RA in Germany (2017-2030)
  • Figure 17: Gender specific Prevalence of RA in Germany (2017-2030)
  • Figure 18: Diagnosed Population of NORDA in Germany (2017-2030)
  • Figure 19: Diagnosed Population of CAD and RA in France (2017-2030)
  • Figure 20: Sub-type Specific Prevalence of RA in France (2017-2030)
  • Figure 21: Gender specific Prevalence of RA in France (2017-2030)
  • Figure 22: Diagnosed Population of NORDA in France (2017-2030)
  • Figure 23: Diagnosed Population of CAD and RA in Italy (2017-2030)
  • Figure 24: Sub-type Specific Prevalence of RA in Italy (2017-2030)
  • Figure 25: Gender specific Prevalence of RA in Italy (2017-2030)
  • Figure 26: Diagnosed Population of NORDA in Italy (2017-2030)
  • Figure 27: Diagnosed Population of CAD and RA in Spain (2017-2030)
  • Figure 28: Sub-type Specific Prevalence of RA in Spain (2017-2030)
  • Figure 29: Gender specific Prevalence of RA in Spain (2017-2030)
  • Figure 30: Diagnosed Population of NORDA in Spain (2017-2030)
  • Figure 31: Diagnosed Population of CAD and RA in the UK (2017-2030)
  • Figure 32: Sub-type Specific Prevalence of RA in the UK (2017-2030)
  • Figure 33: Gender specific Prevalence of RA in the United Kingdom (2017-2030)
  • Figure 34: Diagnosed Population of NORDA in the UK (2017-2030)
  • Figure 35: Diagnosed Population of CAD and RA in Japan (2017-2030)
  • Figure 36: Sub-type Specific Prevalence of RA in Japan (2017-2030)
  • Figure 37: Gender specific Prevalence of RA in Japan (2017-2030)
  • Figure 38: Diagnosed Population of NORDA in Japan (2017-2030)
  • Figure 39: Treatments Addressing Myocardial Perfusion
  • Figure 40: Treatments Addressing Neural Processing
  • Figure 41: Treatment Landscape of Refractory Angina
  • Figure 42: Possible Combinations of Anti-anginal Drugs
  • Figure 43: Technique of enhanced external counterpulsation
  • Figure 44: Possible mechanisms responsible for the clinical benefit associated with EECP therapy
  • Figure 45: Pictorial Representation of Neuromodulation Targets
  • Figure 46: Pictorial Representation of Coronary Sinus Reducer
  • Figure 47: Clinical Assessment of Angina
  • Figure 48: Clinical assessment and the typicality of anginal pain
  • Figure 49: Unmet Needs of RA
  • Figure 50: 7 Major Market Size of RA in USD Million (2017-2030)
  • Figure 51: Market Size of RA in the United States, USD Millions (2017-2030)
  • Figure 52: The U.S. market size of RA by therapies in USD Million (2017-2030)
  • Figure 53: Market Size of RA in Germany, USD Millions (2017-2030)
  • Figure 54: Germany market size of RA by therapies in USD Million (2017-2030)
  • Figure 55: Market Size of RA in France, USD Millions (2017-2030)
  • Figure 56: France market size of RA by therapies in USD Million (2017-2030)
  • Figure 57: Market Size of RA in Italy, USD Millions (2017-2030)
  • Figure 58: Italy market size of RA by therapies in USD Million (2017-2030)
  • Figure 59: Market Size of RA in Spain, USD Millions (2017-2030)
  • Figure 60: Spain market size of RA by therapies in USD Million (2017-2030)
  • Figure 61: Market Size of RA in the UK, USD Millions (2017-2030)
  • Figure 62: The UK market size of RA by therapies in USD Million (2017-2030)
  • Figure 63: Market Size of RA in Japan, USD Millions (2017-2030)
  • Figure 64: Japan market size of RA by therapies in USD Million (2017-2030)
  • Figure 65: Market Drivers
  • Figure 66: Market Barriers